Singh Gurcharan, Lavanya Ms
Department of Dermatology and STD, Sri Devaraj Urs Medical College, Tamaka, Kolar - 563 101, India.
Int J Trichology. 2010 Jan;2(1):36-9. doi: 10.4103/0974-7753.66911.
Alopecia Areata (AA) is a common non-scarring alopecia directed against the anagenic hair follicle. Various treatment modalities have been used for the treatment of severe AA. Topical immunotherapy is the best documented treatment so far for severe and refractory AA. Dinitrochlorobenzene (DNCB), squaric acid dibutylester (SADBE), and diphencyprone (DPCP) are the contact allergens used for this purpose. DNCB has been found to be mutagenic by the Ames test and is largely replaced by DPCP and SADBE. DPCP and SADBE are both known to be non-mutagenic compounds and have comparable efficacy results and relapse rates. SADBE requires special solvents and additives to maintain its potency and is more expensive than the rest. DPCP has a response rate varying from 60% in severe Alopecia Areata to 17% in patients with alopecia totalis or universalis, and shows about 88 to 100% high response rate in patients with patchy Alopecia Areata.
斑秃（AA）是一种常见的非瘢痕性脱发，主要针对生长期毛囊。多种治疗方式已被用于治疗重度斑秃。局部免疫疗法是目前治疗重度和难治性斑秃记录最完备的疗法。二硝基氯苯（DNCB）、二丁基二酯方酸（SADBE）和二苯环丙烯酮（DPCP）是用于此目的的接触性变应原。通过艾姆斯试验发现DNCB具有致突变性，在很大程度上已被DPCP和SADBE取代。已知DPCP和SADBE均为非致突变化合物，且疗效结果和复发率相当。SADBE需要特殊溶剂和添加剂来维持其效力，且比其他药物更昂贵。DPCP的有效率在重度斑秃患者中为60%，在全秃或普秃患者中为17%，在斑秃患者中显示出约88%至100%的高有效率。
